Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29760494 | 1.00 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19698935 | 0.95 | NR1H4 (0.91) | NR1H4HSD17B13 | |
| SCHEMBL19690235 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL29386539 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL29383874 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19690322 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19690327 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL29385824 | 0.94 | NR1H4 (1.00) | NR1H4HSD17B13 | |
| SCHEMBL19689491 | 0.93 | NR1H4 (0.86) | NR1H4HSD17B13 | |
| SCHEMBL30775158 | 0.93 | NR1H4 (0.86) | NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691553-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4534536-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-01-23 | — | — | US | disclosed |
| EP-4089072-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2024-08-28 | — | — | EP | disclosed |
| EP-4360632-A2 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| CN-117924266-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-117924267-A | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-109476636-B | Compounds that modulate FXR (NR 1H 4) | 吉利德科学公司 | 2024-01-09 | — | — | CN | disclosed |
| EP-3911647-B1 | ISOXAZOLE COMPOUND AS FXR AGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3911647-B1 | ISOXAZOLE COMPOUND AS FXR AGONIST AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | GILEAD SCIENCES INC (US) | 2023-12-13 | — | — | EP | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| EP-3257847-B1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| WO-2018089212-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. (US) | 2018-05-17 | — | — | WO | disclosed |
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | GILEAD SCIENCES, INC. | 2018-05-17 | — | — | US | disclosed |
| WO-2017218330-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250026744-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 707/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NR1H4 1/4885HSD17B13 681/4885 |
| US-20180133203-A1 | METHODS OF TREATING LIVER DISEASE | SLC10A1, FXR1, SLC10A2 | NR1H4 4/4885HSD17B13 356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.